실적분석 2026년 7월 30일

Hutchmed ($HCM) 1H 2026 Earnings Analysis — China Products Recover ~40%, Profitability Maintained; Total Revenue Flat, Guidance Held

Earnings Scorecard

Revenue: $278.3 million (prior-year period $277.7 million, essentially flat; ~-4% on constant-currency basis; consensus not confirmed)

EPS: $0.09 per ADS (prior-year period $2.65, base affected by prior-year one-off gain on equity divestiture; consensus not confirmed)

Guidance: Maintained — 2026 oncology/immunology consolidated revenue range of $330 million–$450 million reaffirmed

Share price reaction: -3.42% after-hours ($11) — as of 07-30 20:00 Korea time

Positives

China commercial recovery: Elunate market revenue +41%, Sulanda +45%

Ex-US Fruzaqla: Market revenue approximately +70%; approved and launched in 41 countries

Profitability & cash: Attributable net profit $15.9 million; cash and short-term investments $1.37 billion

China domestic oncology products were at the center of the first-half rebound. Elunate market revenue grew 41% to $60.8 million, supported by expanded reimbursement for endometrial cancer and label/reimbursement updates for kidney cancer. Sulanda grew 45% to $18.4 million, helped by its upgrade to a Category 1 recommendation for grade 1 neuroendocrine tumors in the Chinese Society of Clinical Oncology guidelines. Total China market revenue rose 32% to $94.4 million, with core commercial products (Elunate and Sulanda) up about 42% at $79.2 million.

Ex-US Fruzaqla market revenue increased roughly 70% to $68.9 million, with reimbursement secured in France and launches following in Portugal, Belgium, Korea, Mexico and others, lifting global market revenue to $185.4 million. Consolidated oncology product revenue rose 23% to $121.4 million, also reflecting an $18.1 million milestone from Eli Lilly triggered by the second kidney cancer approval in China.

The company stayed in the black despite higher R&D spending, and cash and short-term investments stood at $1,374.8 million as of end-June, modestly higher than year-end. Late-stage and next-generation pipeline progress was also visible: acceptance of the sovleplenib New Drug Application with priority review, an Orpathys gastric cancer approval, and clinical entry of an antibody-targeted therapy conjugate candidate.

Negatives

Total revenue stagnation: Consolidated revenue essentially flat; ~-4% on constant-currency basis

Sharp net profit decline vs. base: Prior-year divestment gain rolls off, leaving $15.9 million

No guidance raise: Full-year revenue band only reaffirmed

Oncology products sold well, but total consolidated revenue was virtually unchanged from the prior year's $277.7 million at $278.3 million. Other ventures (mainly low-margin prescription drug distribution) revenue fell 14% to $116.0 million, and Takeda-related upfront, regulatory milestone and research services revenue dropped 30% to $20.7 million, weighing on the top line.

Attributable net profit of $15.9 million is still positive, but in a like-for-like comparison with the prior-year $455.0 million (which included an approximately $416.3 million gain on the sale of the 45% stake in Shanghai Hutchison Pharmaceuticals), it looks sharply compressed. Basic EPS per ADS also fell steeply to $0.09 from $2.65. R&D expense rose to $78.8 million and SG&A to $46.5 million, lifting the cost burden.

The full-year oncology/immunology consolidated revenue guidance ($330 million–$450 million) was merely maintained, with no upside signal. Ipsen voluntarily withdrew Tazverik across all markets in March following SYMPHONY-1 safety data, and, given the small-cap profile, analyst consensus coverage is thin, making it difficult to declare a clear beat or miss purely on the numbers.

What Management Said

Management explained that slimming down the China commercial organization and concentrating marketing efforts translated into a rebound in Elunate and Sulanda market revenue. At the same time, they emphasized accelerating antibody-targeted therapy conjugate development, expanding talent and AI capabilities, and holding business development discussions with multinational partners for the global development and commercialization of promising programs.

The non-executive chairman positioned building a globally competitive oncology portfolio anchored in differentiated innovation as the strategic center of gravity, and the company struck a tone of continuing investment in next-generation platforms from a strong cash base. Reaffirming the full-year revenue band as 'maintained' rather than raising it reads as consistent with a market mood that wants execution proof rather than an aggressive growth narrative.

Market Reaction and Forward Catalysts

The market appears to have weighed the stagnant consolidated revenue, the absence of a guidance raise and the year-over-year earnings compression more heavily than the positives of China product recovery and sustained profitability/cash. Underlying oncology growth was confirmed, but the signal of 'company-wide top-line acceleration' was weak, tilting after-hours trading toward a wait-and-see/profit-taking stance. Given the China biotech and small-cap profile, consensus coverage is thin, so the price action is being shaped less by a beat/miss frame and more by year-over-year comparisons and second-half clinical milestones.

Second-half top-line readouts from the savolitinib and surufatinib Phase 3 trials and progress on global/China approval timelines

Outcome of the sovleplenib priority review and the pace of China commercial preparation

Where full-year oncology/immunology consolidated revenue lands within the $330 million–$450 million band, and antibody-targeted therapy conjugate capacity-expansion data